Diagnostics,
Год журнала:
2023,
Номер
13(6), С. 1015 - 1015
Опубликована: Март 7, 2023
Immunotherapy
targeting
PD-1/PD-L1
has
been
proven
to
be
effective
for
cervical
cancer
treatment.
To
explore
non-invasive
examinations
assessing
the
PD-L1
status
in
cancer,
we
performed
a
retrospective
study
investigate
predictive
value
of
18F-FDG
PET/CT.The
correlations
between
expression,
clinicopathological
characteristics
and
PET/CT
metabolic
parameters
were
evaluated
74
patients.
The
included
age,
histologic
type,
tumor
differentiation,
FIGO
stage
size.
maximum
standard
uptake
(SUVmax),
mean
(SUVmean),
total
lesion
glycolysis
(TLG)
volume
(MTV).In
univariate
analysis,
SUVmax,
SUVmean,
TLG,
size
differentiation
obviously
associated
with
status.
SUVmax
(rs
=
0.42)
SUVmean
0.40)
moderately
positively
correlated
combined
positive
score
(CPS)
Spearman
correlation
analysis.
results
multivariable
analysis
showed
that
higher
(odds
ratio
2.849)
lower
degree
(Odds
Ratio
0.168),
greater
probability
being
positive.
ROC
curve
demonstrated
when
cut-off
values
TLG
10.45,
6.75
143.4,
respectively,
highest
accuracy
predicting
expression
was
77.0%,
71.6%
62.2%,
respectively.
comprehensive
ability
assessed
by
combining
PD-L1-negative
rate
100%
low
group,
whereas
PD-L1-positive
84.6%
high
group.
In
addition,
also
found
H-score
HIF-1α
CPS
0.51).The
primary
optimum
predictors
cancer.
There
great
potential
selecting
candidates
PD1/PD-L1
immune
checkpoint
therapy.
Molecular Biomedicine,
Год журнала:
2024,
Номер
5(1)
Опубликована: Ноя. 29, 2024
Abstract
Tumor
energy
metabolism
plays
a
crucial
role
in
the
occurrence,
progression,
and
drug
resistance
of
tumors.
The
study
tumor
has
gradually
become
an
emerging
field
treatment.
Recent
studies
have
shown
that
epigenetic
regulation
is
closely
linked
to
metabolism,
influencing
metabolic
remodeling
biological
traits
cells.
This
review
focuses
on
primary
pathways
explores
therapeutic
strategies
target
these
pathways.
It
covers
key
areas
such
as
glycolysis,
Warburg
effect,
mitochondrial
function,
oxidative
phosphorylation,
adaptability
Additionally,
this
article
examines
regulator
SWI/SNF
complex
specifically
its
interactions
with
glucose,
lipids,
amino
acids.
Summarizing
aimed
at
pathways,
including
inhibitors
mitochondrial-targeted
drugs,
exploitation
vulnerabilities,
recent
developments
related
complexes
potential
targets.
clinical
significance,
challenges,
future
directions
research
are
discussed,
overcome
resistance,
combination
therapy,
application
new
technologies.
Molecules,
Год журнала:
2021,
Номер
26(8), С. 2201 - 2201
Опубликована: Апрель 11, 2021
Immunotherapy
is
an
effective
therapeutic
option
for
several
cancers.
In
the
last
years,
introduction
of
checkpoint
inhibitors
(ICIs)
has
shifted
landscape
in
oncology
and
improved
patient
prognosis
a
variety
neoplastic
diseases.
However,
to
date,
selection
best
patients
eligible
these
therapies,
as
well
response
assessment
still
challenging.
Patients
are
mainly
stratified
using
immunohistochemical
analysis
expression
antigens
on
biopsy
specimens,
such
PD-L1
PD-1,
tumor
cells,
peritumoral
immune
cells
and/or
microenvironment
(TME).
Recently,
use
development
imaging
biomarkers
able
assess
in-vivo
cancer-related
processes
becoming
more
important.
Today,
positron
emission
tomography
(PET)
with
2-deoxy-2-[18F]fluoro-D-glucose
([18F]FDG)
used
routinely
evaluate
metabolism,
also
predict
monitor
immunotherapy.
Although
highly
sensitive,
FDG-PET
general
rather
unspecific.
Novel
radiopharmaceuticals
(immuno-PET
radiotracers),
identify
specific
system
targets,
under
investigation
pre-clinical
clinical
settings
better
highlight
all
mechanisms
involved
this
review,
we
will
provide
overview
main
new
immuno-PET
radiotracers
development.
We
review
players
(immune
molecular
targets)
Furthermore,
report
current
applications
evidence
[18F]FDG
PET
immunotherapy,
including
artificial
intelligence
(AI).
Neoadjuvant
immunochemotherapy
(NICT)
has
shown
promising
therapeutic
benefits
in
patients
with
locally
advanced
gastric
cancer
(LAGC).
Our
study
aimed
to
predict
the
pathological
response
NICT
LAGC
before
surgery
by
correlating
metabolic
parameters
of
baseline
and
post-treatment
18F-fluorodeoxyglucose
(18F-FDG)
positron
emission
tomography/computed
tomography
(PET/CT)
primary
lesion
following
radical
surgery.
Thirty-six
who
received
three
cycles
(combination
sintilimab
CapeOx),
followed
surgery,
were
included
this
study.
Both
18F-FDG
PET/CT
(bPET)
(pPET)
conducted,
derived
from
scans,
including
maximum
standardized
uptake
value
(SUVmax),
tumor
volume
(MTV),
total
glycolysis
(TLG)
on
bPET
pPET
(bSUVmax
pSUVmax,
bMTV
pMTV,
bTLG
pTLG),
as
well
their
reductions
(ΔSUVmax,
ΔMTV,
ΔTLG),
assessed
for
correlation
treatment
efficacy
regression
grade
(TRG)
NICT.
Out
36
patients,
13
had
a
good
(GR),
which
5
cases
TRG
0
8
1.
Conversely,
23
exhibited
poor
(PR),
20
having
2
3
3.
Univariate
analysis
revealed
that
pMTV
pTLG
GR
group
significantly
lower
compared
PR
(all
p
<
0.05).
The
identified
cutoff
values
1.68
cm³
(area
under
cure
(AUC)
=
0.683)
4.71
(AUC
groups,
respectively.
On
receiver
operating
characteristic
(ROC)
curve
analyses,
these
corresponded
sensitivity,
specificity,
accuracy
68.8%,
80.0%,
73.1%,
respectively,
no
statistically
significant
differences
between
them
after
DeLong
test
McNemar
>
Furthermore,
bSUVmax,
bMTV,
bTLG,
ΔSUVmax,
ΔTLG
higher
than
those
1
Upon
performing
ROC
analyses
group,
thresholds
determined
be
7.8
0.916),
36.76
0.768),
105.55
0.819),
4.82
0.923),
22.64
0.807),
104.7
0.845),
These
demonstrated
high
sensitivity
(80%
100%
others),
specificity
(83.9%,
71.0%,
67.7%,
83.9%,
61.3%,
71.0%),
(86.1%,
66.7%,
72.2%,
86.1%,
75.0%)
predicting
NICT,
Imaging
biomarkers
combination
showed
potential
Cancers,
Год журнала:
2021,
Номер
13(18), С. 4543 - 4543
Опубликована: Сен. 10, 2021
Lung
cancer
remains
the
leading
cause
of
cancer-related
death,
and
it
is
usually
diagnosed
in
advanced
stages
(stage
III
or
IV).
Recently,
availability
targeted
strategies
immunotherapy
with
checkpoint
inhibitors
(ICI)
has
favorably
changed
patient
prognosis.
Treatment
outcome
closely
related
to
tumor
biology
interaction
immune
microenvironment
(TME).
While
response
molecular
therapies
relies
on
presence
specific
genetic
alterations
cells,
accurate
ICI
biomarkers
are
lacking,
clinical
likely
depends
multiple
factors
that
both
host
tumor-related.
This
paper
an
overview
ongoing
research
predictive
from
vitro/ex
vivo
analysis
(ranging
conventional
pathology
biology)
analysis,
where
imaging
showing
exponential
growth
use
due
technological
advancements
new
bioinformatics
approaches
applied
image
analyses
allow
recovery
features
subclones.
Biomedicines,
Год журнала:
2022,
Номер
10(5), С. 1181 - 1181
Опубликована: Май 20, 2022
While
promising,
PD-L1
expression
on
tumor
tissues
as
assessed
by
immunohistochemistry
has
been
shown
to
be
an
imperfect
biomarker
that
only
applies
a
limited
number
of
cancers,
whereas
many
patients
with
PD-L1-negative
tumors
still
respond
anti-PD-(L)1
immunotherapy.
Recent
studies
using
patient
blood
samples
assess
immunotherapeutic
responsiveness
suggests
promising
approach
the
identification
novel
and/or
improved
biomarkers
for
In
this
review,
we
discuss
advances
in
our
evolving
understanding
regulation
and
function
expression,
which
is
foundation
developing
blood-based
We
further
current
knowledge
clinical
study
results
immune
cells,
exosomes,
soluble
forms
peripheral
blood.
Finally,
key
challenges
successful
development
potential
use
